BI
BVF Inc Portfolio holdings
AUM
$2.8B
This Quarter Return
+19.43%
1 Year Return
+17.96%
3 Year Return
+404.14%
5 Year Return
+563.41%
10 Year Return
+5,885.83%
AUM
$567M
AUM Growth
+$567M
(+18%)
Cap. Flow
-$7.26M
Cap. Flow
% of AUM
-1.28%
Top 10 Holdings %
Top 10 Hldgs %
70.26%
Holding
36
New
5
Increased
5
Reduced
14
Closed
6
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$41.9M |
| 2 |
CNCE
Concert Pharmaceuticals, Inc.
CNCE
|
$17.6M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$9.68M |
| 4 |
LOXO
Loxo Oncology, Inc
LOXO
|
$8.82M |
| 5 |
Xenon Pharmaceuticals
XENE
|
$3.31M |
Top Sells
| 1 |
Ligand Pharmaceuticals
LGND
|
$20.6M |
| 2 |
CASC
Cascadian Therapeutics, Inc.
CASC
|
$17.1M |
| 3 |
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
|
$12.2M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$8.5M |
| 5 |
Exelixis
EXEL
|
$8.36M |
Sector Composition
| 1 | Healthcare | 62.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
| $66.1M | 11.67% | 9,169,276 -236,541 | -3% | -$1.71M |
|
|
CCXI
2
DELISTED
ChemoCentryx, Inc.
CCXI
| $59.8M | 10.56% | 7,270,013 -1,033,071 | -12% | -$8.5M |
|
|
BPMC
3
DELISTED
Blueprint Medicines
BPMC
| $41.9M | 7.4% | +1,582,408 | New | +$41.9M |
|
|
FWP
4
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
| $38.4M | 6.78% | 1,008,981 -168,500 | -14% | -$6.41M |
|
|
CNCE
5
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $37.5M | 6.63% | 2,521,452 +1,180,793 | +88% | +$17.6M |
|
|
CASC
6
DELISTED
Cascadian Therapeutics, Inc.
CASC
| $36.5M | 6.44% | 9,754,178 -4,560,000 | -32% | -$17.1M |
|
|
LOXO
7
DELISTED
Loxo Oncology, Inc
LOXO
| $29.1M | 5.14% | 1,615,081 +489,416 | +43% | +$8.82M |
|
|
OMED
8
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $28.5M | 5.02% | 1,264,715 -19,400 | -2% | -$436K |
|
9
Ironwood Pharmaceuticals
IRWD
$214M
| $26.2M | 4.62% | 2,171,108 | – | – |
|
|
VTAE
10
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
| $23.1M | 4.08% | 1,604,615 +27,180 | +2% | +$391K |
|
|
TBRA
11
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
| $20.3M | 3.58% | 1,175,233 -707,288 | -38% | -$12.2M |
|
12
Gyre Therapeutics
GYRE
$703M
| $18.6M | 3.28% | 6,655,128 | – | – |
|
|
ONCT
13
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
| $15.8M | 2.79% | 10,772,306 -338,805 | -3% | -$498K |
|
|
QLTI
14
DELISTED
QLT Inc
QLTI
| $15.4M | 2.72% | 3,737,446 -412,416 | -10% | -$1.7M |
|
15
Cytokinetics
CYTK
$4.23B
| $14.2M | 2.5% | 2,106,989 | – | – |
|
|
16
Exelixis
EXEL
$10.1B
| $10.4M | 1.84% | 2,766,152 -2,222,205 | -45% | -$8.36M |
|
|
ARQL
17
DELISTED
Arqule Inc
ARQL
| $10.3M | 1.82% | 6,430,708 +256,147 | +4% | +$410K |
|
|
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.68M | 1.71% | +200,000 | New | +$9.68M |
|
|
19
Xenon Pharmaceuticals
XENE
$2.98B
| $7.83M | 1.38% | 678,764 +287,340 | +73% | +$3.31M |
|
|
FPRX
20
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $5.98M | 1.05% | 240,597 -262,235 | -52% | -$6.51M |
|
21
Astria Therapeutics
ATXS
$349M
| $2.75M | 0.48% | +225,000 | New | +$2.75M |
|
22
Savara
SVRA
$567M
| $2.51M | 0.44% | 5,111,293 -2,130,307 | -29% | -$1.04M |
|
|
ATYR
23
aTyr Pharma
ATYR
$527M
| $2.5M | 0.44% | +134,725 | New | +$2.5M |
|
24
Achieve Life Sciences
ACHV
$152M
| $2.38M | 0.42% | 1,020,108 -348,392 | -25% | -$812K |
|
|
GBIM
25
DELISTED
GLOBEIMMUNE INC COM STK (DE)
GBIM
| $1.77M | 0.31% | +678,400 | New | +$1.77M |
|